在大鼠中,OATP2B1和阿托瓦斯塔丁对甲林异构体的影响
Jonny Kinzi1, Markus Grube2, Janine Hussner1
1Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
有机阴离子载体聚酸 (OATPs) 影响共氨酸 (CP) 水平. 阿托瓦斯塔丁增加了CP,而OATP2B1基因淘汰意外降低了基底CP,表明OATP2B1B1.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 甲 (CPI和CPIII) 是有机离子转运聚酸 (OATP) 的潜在生物标志物.
- OATPs在通过细胞膜运输各种有机离子 (包括氨酸) 中起着至关重要的作用.
- 了解OATP的功能对于解释生物标志物水平和药物相互作用至关重要.
研究的目的:
- 调查OATP2B1和OATP1B2在调节血清中coproporphyrin I (CPI) 和coproporphyrin III (CPIII) 水平中的作用.
- 评估阿托瓦斯塔丁 (一种OATP抑制剂) 对不同老鼠模型中的CP水平的影响.
- 阐明OATP2B1对基底CP血清度的特定贡献.
主要方法:
- 使用了野生类型,rSlco2b1-Knockout和SLCO2B1-人性化的老鼠模型.
- 测量血清CPI和CPIII水平在基线和阿托瓦斯塔丁服用后.
- 分析了对CP水平的基因型特异性影响,以应对OATP抑制.
主要成果:
- 在所有大鼠群体中,阿托瓦斯塔丁的使用显著增加了血清CPI和CPIII水平,表明OATP抑制.
- 与野生类型相比,rSlco2b1-Knockout大鼠的基础血清CPI水平显著较低.
- 基础血清CPIII水平不受rSlco2b1淘汰的影响,但在阿托瓦斯塔丁的存在下,对CPI和CPIII的基因型影响被取消了.
结论:
- 在老鼠中,OATP2B1对基底血清中甲氨酸水平产生了意想不到且显著的影响.
- 阿托瓦斯塔丁的OATP抑制取代了基因型特异性的CP水平差异.
- 这些发现突出了OATP载体和氨酸代谢之间的复杂相互作用.
更多相关视频
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
08:28Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
相关概念视频
Hepatic Drug Excretion: Influencing Factors
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
